143 related articles for article (PubMed ID: 26037205)
21. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.
Dasmahapatra GP; Didolkar P; Alley MC; Ghosh S; Sausville EA; Roy KK
Clin Cancer Res; 2004 Aug; 10(15):5242-52. PubMed ID: 15297428
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo.
Xu M; Xie XH; Xie XY; Xu ZF; Liu GJ; Zheng YL; Huang GL; Wang W; Zheng SG; Lü MD
Acta Radiol; 2013 Mar; 54(2):199-204. PubMed ID: 23171528
[TBL] [Abstract][Full Text] [Related]
23. Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma.
Ou DL; Chang CJ; Jeng YM; Lin YJ; Lin ZZ; Gandhi AK; Liao SC; Huang ZM; Hsu C; Cheng AL
J Gastroenterol Hepatol; 2014 Dec; 29(12):2021-31. PubMed ID: 25160036
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent.
Vandewynckel YP; Laukens D; Geerts A; Vanhove C; Descamps B; Colle I; Devisscher L; Bogaerts E; Paridaens A; Verhelst X; Van Steenkiste C; Libbrecht L; Lambrecht BN; Janssens S; Van Vlierberghe H
Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):861-70. PubMed ID: 24987823
[TBL] [Abstract][Full Text] [Related]
25. The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma.
Kumar A; Fillmore HL; Kadian R; Broaddus WC; Tye GW; Van Meter TE
Mol Cancer Res; 2009 Nov; 7(11):1813-21. PubMed ID: 19887560
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous inhibition of tumor growth and angiogenesis for resistant hepatocellular carcinoma by co-delivery of sorafenib and survivin small hairpin RNA.
Shen J; Sun H; Meng Q; Yin Q; Zhang Z; Yu H; Li Y
Mol Pharm; 2014 Oct; 11(10):3342-51. PubMed ID: 24495194
[TBL] [Abstract][Full Text] [Related]
27. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.
Galuppo R; Maynard E; Shah M; Daily MF; Chen C; Spear BT; Gedaly R
Anticancer Res; 2014 Apr; 34(4):1709-13. PubMed ID: 24692700
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
29. Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma.
Stefanovic M; Tutusaus A; Martinez-Nieto GA; Bárcena C; de Gregorio E; Moutinho C; Barbero-Camps E; Villanueva A; Colell A; Marí M; García-Ruiz C; Fernandez-Checa JC; Morales A
Oncotarget; 2016 Feb; 7(7):8253-67. PubMed ID: 26811497
[TBL] [Abstract][Full Text] [Related]
30. Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice.
Zhao L; Chen Z; Wang J; Yang L; Zhao Q; Wang J; Qi Q; Mu R; You QD; Guo QL
Cancer Chemother Pharmacol; 2010 Feb; 65(3):481-9. PubMed ID: 19585117
[TBL] [Abstract][Full Text] [Related]
31. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
Piguet AC; Saar B; Hlushchuk R; St-Pierre MV; McSheehy PM; Radojevic V; Afthinos M; Terracciano L; Djonov V; Dufour JF
Mol Cancer Ther; 2011 Jun; 10(6):1007-17. PubMed ID: 21487053
[TBL] [Abstract][Full Text] [Related]
32. Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis.
Vinall RL; Hwa K; Ghosh P; Pan CX; Lara PN; de Vere White RW
Clin Cancer Res; 2007 Oct; 13(20):6204-16. PubMed ID: 17947488
[TBL] [Abstract][Full Text] [Related]
33. Identification of a novel oxidative stress induced cell death by Sorafenib and oleanolic acid in human hepatocellular carcinoma cells.
Lange M; Abhari BA; Hinrichs TM; Fulda S; Liese J
Biochem Pharmacol; 2016 Oct; 118():9-17. PubMed ID: 27544320
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
[TBL] [Abstract][Full Text] [Related]
35. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
Horwitz E; Stein I; Andreozzi M; Nemeth J; Shoham A; Pappo O; Schweitzer N; Tornillo L; Kanarek N; Quagliata L; Zreik F; Porat RM; Finkelstein R; Reuter H; Koschny R; Ganten T; Mogler C; Shibolet O; Hess J; Breuhahn K; Grunewald M; Schirmacher P; Vogel A; Terracciano L; Angel P; Ben-Neriah Y; Pikarsky E
Cancer Discov; 2014 Jun; 4(6):730-43. PubMed ID: 24687604
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
Sprinzl MF; Reisinger F; Puschnik A; Ringelhan M; Ackermann K; Hartmann D; Schiemann M; Weinmann A; Galle PR; Schuchmann M; Friess H; Otto G; Heikenwalder M; Protzer U
Hepatology; 2013 Jun; 57(6):2358-68. PubMed ID: 23424039
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
Guidetti A; Carlo-Stella C; Locatelli SL; Malorni W; Mortarini R; Viviani S; Russo D; Marchianò A; Sorasio R; Dodero A; Farina L; Giordano L; Di Nicola M; Anichini A; Corradini P; Gianni AM
Clin Cancer Res; 2014 Nov; 20(22):5641-51. PubMed ID: 25239609
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
Hideshima T; Catley L; Raje N; Chauhan D; Podar K; Mitsiades C; Tai YT; Vallet S; Kiziltepe T; Ocio E; Ikeda H; Okawa Y; Hideshima H; Munshi NC; Yasui H; Richardson PG; Anderson KC
Br J Haematol; 2007 Sep; 138(6):783-91. PubMed ID: 17760810
[TBL] [Abstract][Full Text] [Related]
39. Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.
Wild AT; Gandhi N; Chettiar ST; Aziz K; Gajula RP; Williams RD; Kumar R; Taparra K; Zeng J; Cades JA; Velarde E; Menon S; Geschwind JF; Cosgrove D; Pawlik TM; Maitra A; Wong J; Hales RK; Torbenson MS; Herman JM; Tran PT
PLoS One; 2013; 8(6):e65726. PubMed ID: 23762417
[TBL] [Abstract][Full Text] [Related]
40. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
Ho V; Lim TS; Lee J; Steinberg J; Szmyd R; Tham M; Yaligar J; Kaldis P; Abastado JP; Chew V
Oncotarget; 2015 Sep; 6(29):27252-66. PubMed ID: 26287667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]